{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:50:00Z","timestamp":1788292200051,"version":"build-2803163510"},"reference-count":40,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The overall- and progression-free survival rates of Hodgkin\u2019s lymphoma patients have improved. Our goal was to examine the changes in our treatment results and their causes depending on the daily diagnostic and therapeutic practice. Materials and Methods: We analysed data of 776 classical Hodgkin lymphoma patients treated between 1980 and 2019. Patient data were investigated in ten-year periods (first period: 1980\u20131989, second period: 1990\u20131999, third period: 2000\u20132009, and fourth period: 2010\u20132019). Results: Radiotherapy alone as a first-line treatment was used progressively less often, and in the 4th period it was no longer used before or without chemotherapy. The use of combined chemo- and radiotherapy decreased in the last period, and the number of those patients who received only chemotherapy increased significantly. The 10-year overall survival improved significantly from 1990 to 1999 compared to 2010 to 2019 (74.9% vs. 86.9%). About 30% of patients relapsed after or were refractory to first-line therapy in each period. The incidence of relapse in the last period did not increase after two years, but there was no significant difference between the periods. Conclusions: Overall survival rates of HL patients have improved significantly in recent decades, which is due to improved diagnostic methods and modern therapies. Progression-free survival is unchanged; one-third of patients relapse or are refractory to first-line treatment within the first two years. Early recognition of R\/R patients, the early application of newer and already available innovative therapies, and the finding of additional new and effective therapies are of particular importance.<\/jats:p>","DOI":"10.3390\/medicina60081272","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T08:42:28Z","timestamp":1723020148000},"page":"1272","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Effect of Diagnostic and Therapeutic Changes on the Survival of Hodgkin\u2019s Lymphoma Patients (1980\u20132019)"],"prefix":"10.3390","volume":"60","author":[{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogl\u00e1rka","family":"Dob\u00f3","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanni","family":"Borics","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1vid","family":"T\u00f3thfalusi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0453-1709","authenticated-orcid":false,"given":"L\u00e1szl\u00f3 Imre","family":"Pincz\u00e9s","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3507-9997","authenticated-orcid":false,"given":"Zs\u00f3fia","family":"Milt\u00e9nyi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD Plus Subtotal Nodal Versus Involved-Field Radiotherapy in Early-Stage Hodgkin\u2019s Disease: Long-Term Results","volume":"22","author":"Bonfante","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin\u2019s Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study","volume":"27","author":"Engert","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/hon.824","article-title":"What is the price of survival in Hodgkin\u2019s lymphoma? Long-term follow-up of cured patients","volume":"25","author":"Katalin","year":"2007","journal-title":"Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1556\/650.2015.30260","article-title":"\u00daj lehet\u0151s\u00e9gek a refrakter \u00e9s relab\u00e1lt Hodgkin-lymphom\u00e1s betegek kezel\u00e9s\u00e9ben [Novel treatment options in relapsed and refracter Hodgkin lymphomas]","volume":"156","author":"Simon","year":"2015","journal-title":"Orv. Hetil."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early Positron Emission Tomography Response\u2013Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Girinsky","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin\u2019s Lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron Emission Tomography\u2013Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_8","unstructured":"(2024, July 24). NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma (Version V.3. 2024). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: A phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0140-6736(69)90435-8","article-title":"The Hodgkin Maze","volume":"294","author":"Davidson","year":"1969","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_15","first-page":"1860","article-title":"Report of the Committee on Hodgkin\u2019s Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_18","first-page":"104","article-title":"The role of FDG-PET in Hodgkin lymphoma","volume":"21","author":"Subocz","year":"2017","journal-title":"Contemp. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJM198506203122504","article-title":"The Will Rogers Phenomenon: Stage Migration and New Diagnostic Techniques as a Source of Misleading Statistics for Survival in Cancer","volume":"312","author":"Feinstein","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cam4.655","article-title":"Improved survival time trends in Hodgkin\u2019s lymphoma","volume":"5","author":"Koshy","year":"2016","journal-title":"Cancer Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/1040-8428(92)90021-H","article-title":"Hodgkin\u2019s disease","volume":"13","author":"Kaufman","year":"1992","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_23","unstructured":"Connors, J.M., Reece, D.E., Diehl, V., and Engert, A. (1998). Hodgkin\u2019s lymphoma: New approaches to treatment. Hematology, 274\u2013295."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2040620711402414","article-title":"Long-term survivorship at a price: Late-term, therapy-associated toxicities in the adult hodgkin lymphoma patient","volume":"2","author":"Straus","year":"2011","journal-title":"Ther. Adv. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","article-title":"Combination chemotherapy of Hodgkin\u2019s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP","volume":"36","author":"Bonadonna","year":"1975","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/02841860151116240","article-title":"Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in Hodgkin\u2019s disease","volume":"40","author":"Brandt","year":"2001","journal-title":"Acta Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11899-007-0022-2","article-title":"Is BEACOPP better than ABVD?","volume":"2","author":"Cheson","year":"2007","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Pei, F., Yu, Y., Dong, B., Guan, H., Dong, X., and Zhao, F. (2021). Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.694545"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hon.3131","article-title":"Long-term outcomes in Hodgkin lymphoma survivors. Temporary trends and comparison with general population","volume":"41","author":"Clemente","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/bloodadvances.2021005150","article-title":"Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: Final results of FIL HD0801 trial","volume":"5","author":"Ricardi","year":"2021","journal-title":"Blood Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2478\/prilozi-2022-0027","article-title":"Milestones in Hematology and Oncology: From Fatal to Curable Disease: Progress in the management of patients with Hodgkin\u2019s lymphoma in the Republic of North Macedonia: Experience from 40 years of population-based study","volume":"43","author":"Amzai","year":"2022","journal-title":"PRILOZI"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.21.01552","article-title":"Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress","volume":"39","author":"Bartlett","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin\u2019s Lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): A multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.HS9.0000890668.27643.97","article-title":"P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD \u00b1 ISRT with brentuximab vedotin+AVD \u00b1 ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma","volume":"6","author":"Radford","year":"2022","journal-title":"Hemasphere"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: Final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial","volume":"41","author":"Meissner","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): A randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/8\/1272\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:31:09Z","timestamp":1760110269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/8\/1272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["medicina60081272"],"URL":"https:\/\/doi.org\/10.3390\/medicina60081272","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]}}}